We believe in helping people who are struggling with serious and debilitating diseases.
Learn More About UsSCIENCE
Delivering On
Unmet Needs
Unmet Needs
Every day we tackle tough challenges in science and medicine. Our teams work diligently to develop smart options that will enable healthcare providers to offer safe and effective treatments for devastating illnesses.
AMYOTROPHIC LATERAL SCLEROSIS
Our Relentless Commitment
Many people living with amyotrophic lateral sclerosis (ALS) have unmet medical needs. We are committed to doing our best to find solutions that may help address those needs.
Oct 21, 2024
Mitsubishi Tanabe Pharma America Presents New Results of RADICAVA ORS® (edaravone) from a Phase 3b Efficacy and Safety Extension Study and a Clinical Analysis of Multiple Studies at NEALS 2024
Read More
Oct 17, 2024
Mitsubishi Tanabe Pharma America Unveils New ALS Research Findings at NEALS 2024 Annual Meeting
Read More
Oct 15, 2024
Mitsubishi Tanabe Pharma America to Showcase ALS Research at 2024 AANEM Annual Meeting
Read More
Company Statement
Oct 10, 2024
Mitsubishi Tanabe Pharma America to Showcase New RADICAVA ORS® (edaravone) Real-World Data at 2024 Academy of Managed Care Pharmacy Nexus Meeting
Read More
Company Statement
Oct 10, 2024
Mitsubishi Tanabe Pharma America to Discontinue Intravenous (IV) RADICAVA® (edaravone)
Read More
You are leaving this website, hosted by Mitsubishi Tanabe Pharma America, Inc.
This link will take you to a website to which our Privacy Policy and Terms of Use does
not apply. Mitsubishi Tanabe Pharma America, Inc. does not control the content of this third-party site.